Minigastrin

Minigastrin
Identifiers
CAS Number	101212-63-9 ;
3D model (JSmol)	Interactive image;
ChemSpider	17287721 ;
PubChem CID	16131008;
UNII	262J9O2552 ;
CompTox Dashboard (EPA)	DTXSID00143789 ;
	InChI InChI=1S/C74H99N15O26S/c1-37(2)30-44(75)65(106)81-47(19-24-58(94)95)68(109)83-49(21-26-60(98)99)70(111)85-50(22-27-61(100)101)71(112)84-48(20-25-59(96)97)69(110)82-46(18-23-57(92)93)67(108)79-38(3)64(105)88-53(32-40-14-16-42(90)17-15-40)66(107)78-36-56(91)80-54(33-41-35-77-45-13-9-8-12-43(41)45)73(114)86-51(28-29-116-4)72(113)89-55(34-62(102)103)74(115)87-52(63(76)104)31-39-10-6-5-7-11-39/h5-17,35,37-38,44,46-55,77,90H,18-34,36,75H2,1-4H3,(H2,76,104)(H,78,107)(H,79,108)(H,80,91)(H,81,106)(H,82,110)(H,83,109)(H,84,112)(H,85,111)(H,86,114)(H,87,115)(H,88,105)(H,89,113)(H,92,93)(H,94,95)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t38-,44-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-/m0/s1 Key: HRSUIUNCTPSRLR-SOLHVGTRSA-N ;
	SMILES C[C@@H](C(=O)N[C@@H](Cc1ccc(cc1)O)C(=O)NCC(=O)N[C@@H](Cc2c[nH]c3c2cccc3)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc4ccccc4)C(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)N;
Properties
Chemical formula	C70H91N15O26
Molar mass	1558.56 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Minigastrin (also mini gastrin) is a form of gastrin. Its sequence is H-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2.[1]

Minigastrin has shown to be a potential therapeutic agent for thyroid carcinoma by targeting cancer-promoting cholecystokinin receptors[2] A 2018 study further elaborates by using radiochemical labeling to show that Indium-111 labeled minigastrin peptides showing to have stronger affinity to cholecystokinin B receptors (CCK2) in neuroendocrine cancers.[3]

References

Oxford dictionary of biochemistry and molecular biology (Rev. ed.). Oxford University Press. ISBN 9780198529170.
von Guggenberg, Elisabeth; Rangger, Christine; Sosabowski, Jane; Laverman, Peter; Reubi, Jean-Claude; Virgolini, Irene Johanna; Decristoforo, Clemens (6 July 2011). "Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies". Molecular Imaging and Biology. 14 (3): 366–375. doi:10.1007/s11307-011-0506-2.
Rizvi, Syed Faheem Askari; Naqvi, Syed Ali Raza; Roohi, Samina; Sherazi, Tauqir A.; Rasheed, Rashid (24 August 2018). "177Lu-DOTA-coupled minigastrin peptides: promising theranostic agents in neuroendocrine cancers". Molecular Biology Reports. 45 (6): 1759–1767. doi:10.1007/s11033-018-4319-0.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Oxford dictionary of biochemistry and molecular biology (Rev. ed.). Oxford University Press. ISBN 9780198529170.

[2] von Guggenberg, Elisabeth; Rangger, Christine; Sosabowski, Jane; Laverman, Peter; Reubi, Jean-Claude; Virgolini, Irene Johanna; Decristoforo, Clemens (6 July 2011). "Preclinical Evaluation of Radiolabeled DOTA-Derivatized Cyclic Minigastrin Analogs for Targeting Cholecystokinin Receptor Expressing Malignancies". Molecular Imaging and Biology. 14 (3): 366–375. doi:10.1007/s11307-011-0506-2.

[3] Rizvi, Syed Faheem Askari; Naqvi, Syed Ali Raza; Roohi, Samina; Sherazi, Tauqir A.; Rasheed, Rashid (24 August 2018). "177Lu-DOTA-coupled minigastrin peptides: promising theranostic agents in neuroendocrine cancers". Molecular Biology Reports. 45 (6): 1759–1767. doi:10.1007/s11033-018-4319-0.